查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胃癌治疗市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按治疗类型、癌症类型、给药途径、治疗类别、分销渠道、地理细分、竞争
市场调查报告书
商品编码
1255250

胃癌治疗市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按治疗类型、癌症类型、给药途径、治疗类别、分销渠道、地理细分、竞争

Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment Type, By Cancer Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球胃癌治疗市场预计在预测期内将出现显着增长。

这是由于治疗胃癌的新药和治疗方法的开发取得了进展。 此外，对较少痛苦和低成本治疗的需求增加以及癌症治疗的有利报销方案正在显着推动世界各地胃癌治疗的增长。 此外，预计到 2028 年，容易患胃癌等慢性病的老龄化社会的到来将增加对各种癌症治疗的需求，并加速市场增长。 此外，在预测期内，人们对新疗法益处的认识不断提高，全球癌症疾病支出的增加预计将进一步支持胃癌治疗市场。

胃癌患病率增加

全球范围内腺癌、淋巴瘤和胃肠道间质瘤发病率的增加推动了预测期内的市场增长。 同样，日益老龄化的人口，尤其是老年男性，更容易患胃癌等慢性病，胃癌是世界上最常见的致命癌症之一。 预计这将在预测期内推动市场增长。 据美国国家癌症研究所估计，2022 年美国将有 26,380 例胃癌新发病例，并有 11,090 例死亡。 在新兴国家，男性比女性更容易被诊断出胃癌，因为女性的细胞中有某些保护基因的额外拷贝，而男性则没有。 该地区胃癌患病率不断上升，需要有效的治疗方法来治疗患者，预计这将在预测期内推动市场增长。 例如，根据加拿大癌症协会公布的2021年统计数据，有4000名加拿大人患有胃癌。

医疗保健行业的崛起

由于政府对新开发药物的批准增加以及胃癌患病率的增加，预计胃癌市场将在多年内创造有利可图的增长前景。 研发活动在新药和治疗的开发中发挥着重要作用。 例如，台湾的一个研究团队最近发表了两种胃癌生物标誌物。 这一进步可以为胃癌市场带来显着的增长前景，并推动市场增长。 同样，口服药物也有望在预测期内促进市场增长，因为大多数产品都是胶囊或片剂，这使它们成为非常可行的给药途径。 公众健康意识的提高有望推动胃癌治疗市场的增长。 胃癌治疗创新疗法的推出有望同时加强市场。 各种研究人员和政府机构正在投资开发不仅有利于患者而且有利于市场的新药，这在市场上创造了更多机会。 据估计，到 2022 年，美国将有 11,090 人死于这种疾病（6,690 名男性和 4,400 名女性）。 到 2020 年，全球估计有 768,793 人死于胃癌。

近期发展

例如，2021年4月，美国FDA批准Bristol-Myers Squibb K.K.产品Opdivo与氟嘧啶和含铂化疗联合用于治疗转移性胃癌。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第五章胃癌药物全球市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型（免疫疗法、靶向疗法、化学疗法、放射疗法、其他）
    • 按癌症类型（胃癌/胃食管交界处癌/胃肠道间质瘤）
    • 通过给药途径（口服/注射）
    • 按药物类别（PD-1/PD-L1 抑製剂、HER2 拮抗剂、VEGFR2 拮抗剂等）
    • 按分销渠道（医院药房、专业药房、其他）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按地区

第六章北美胃癌治疗市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 加拿大
    • 墨西哥

第七章欧洲胃癌治疗市场前景

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第八章亚太胃癌治疗市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第9章南美洲胃癌治疗市场前景

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章中东和非洲的胃癌治疗市场前景

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按治疗类型
    • 按癌症类型
    • 按给药途径
    • 按治疗类别
    • 按分销渠道
    • 按国家
  • MEA：国家分析
    • 南非胃癌治疗
    • 沙特阿拉伯的胃癌治疗
    • 阿联酋胃癌治疗
    • 土耳其的胃癌治疗
    • 埃及胃癌治疗

第 11 章市场动态

  • 主持人
  • 任务

第12章市场趋势与发展

  • 近期趋势
  • 併购
  • 产品发布

第13章竞争格局

  • 业务概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT 分析
    • Pfizer, Inc.
    • Novartis International AG
    • Eli Lilly and Company
    • Bristol Myers Squibb Company
    • Teva Pharmaceutical Industries AG
    • F. Hoffmann La Roche AG
    • Mylan N.V.
    • Celltrion Healthcare Co., Ltd
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.

第 14 章战略建议

简介目录
Product Code: 14348

The global stomach cancer treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenarios for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, the growing aging population across the globe, which is more prone to different kinds of chronic diseases like stomach cancer, is further expected to increase the demand for different cancer therapies, thereby fuelling market growth through 2028. Besides, growing awareness about the benefits of new therapies, with increasing expenditure on cancer diseases worldwide, is further expected to support the stomach cancer treatment market during the forecast period.

Growing Prevalence of Stomach Cancer

Increasing incidences of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the world are driving market growth during the forecast period. Similarly, the rising aging population is susceptible to chronic diseases like stomach cancer, which is one of the most common deadly cancers worldwide, especially among older males. This is expected to boost market growth in the forecast period. According to National Cancer Institute, in 2022, 26,380 new stomach cancer cases and 11,090 deaths are estimated in the United States. In developing countries, stomach cancer is more diagnosed in males than females because females carry an extra copy of certain protective genes in their cells that men don't have. The increasing prevalence of gastric cancer in the region is demanding effective therapies for treating patients, which, in turn, is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were affected by gastric cancer.

Growing Development In Healthcare Industry

Increasing approval of newly developed drugs from the government, along with the growing prevalence of stomach cancer, is expected to create a lucrative growth prospect for the stomach cancer market over the years. Research & Development activities play a major role in developing novel drugs and therapies. For instance, a research team from Taiwan has recently launched two gastric cancer biomarkers. This advancement may bring remarkable growth prospects for the stomach cancer market, thereby boosting the market growth. Similarly, oral drugs are expected to boost market growth during the forecast period as most products are available in capsules and tablets, making it a very feasible route of administration. Growing health awareness among the population is expected to boost the stomach cancer treatment market growth. The innovative therapy launches for treating gastric cancer are expected to enhance the market simultaneously. Different researchers and government organizations are investing in the development of novel drugs that benefit the market as well as the patient; this creates more opportunities in the market. It is estimated that 11,090 deaths (6,690 men and 4,400 women) from this disease will occur in the United States in 2022. In 2020, an estimated 768,793 people died from stomach cancer worldwide.

Market Segmentation

The global stomach cancer treatment market can be segmented by treatment type, cancer type, route of administration, drug class, distribution channel, and by region. Based on treatment type, the market can be segmented into Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, and Others. Based on cancer type, the market can be differentiated into Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors. Based on the route of administration, the market can be divided into Oral v/s Injectables. Based on drug class, the market can be segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, and Others. Based on distribution channels, the market can be grouped into Hospital Pharmacies, Specialty Pharmacies, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global stomach cancer treatment market on account of the growing demand for advanced cancer therapy in the country.

Market Players

Pfizer, Inc., Novartis International AG, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries AG, F. Hoffmann La Roche AG, Mylan N.V., Celltrion Healthcare Co., Ltd, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. are some of the leading players operating in the Global Stomach Cancer Treatment Market.

Recent Developments

For instance, in April 2021, the U.S. FDA approved Bristol-Myers Squibb Company's product Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of metastatic gastric cancer.

Report Scope

In this report, global stomach cancer treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Stomach Cancer Treatment Market, By Treatment Type:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Others

Stomach Cancer Treatment Market, By Cancer Type:

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Market, By Route of Administration:

  • Oral
  • Injectables

Stomach Cancer Treatment Market, By Drug Class:

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

Stomach Cancer Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

Stomach Cancer Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Stomach Cancer Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stomach Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
    • 5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
    • 5.2.3. By Route of Administration (Oral v/s Injectables)
    • 5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Drug Class
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Stomach Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Drug Class
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stomach Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Drug Class
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Stomach Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Drug Class
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Stomach Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Drug Class
        • 6.3.3.2.5. By Distribution Channel

7. Europe Stomach Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Drug Class
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Stomach Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Drug Class
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Stomach Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Drug Class
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Drug Class
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Stomach Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Drug Class
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Stomach Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Drug Class
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Stomach Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Drug Class
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stomach Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Drug Class
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Stomach Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Drug Class
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Stomach Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Drug Class
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Stomach Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Drug Class
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Stomach Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Drug Class
        • 8.3.5.2.5. By Distribution Channel

9. South America Stomach Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Drug Class
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stomach Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Drug Class
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Stomach Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Drug Class
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Stomach Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Drug Class
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Stomach Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Drug Class
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stomach Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Drug Class
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Drug Class
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Stomach Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Drug Class
        • 10.3.3.2.5. By Distribution Channel
    • 10.3.4. Turkey Stomach Cancer Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment Type
        • 10.3.4.2.2. By Cancer Type
        • 10.3.4.2.3. By Route of Administration
        • 10.3.4.2.4. By Drug Class
        • 10.3.4.2.5. By Distribution Channel
    • 10.3.5. Egypt Stomach Cancer Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment Type
        • 10.3.5.2.2. By Cancer Type
        • 10.3.5.2.3. By Route of Administration
        • 10.3.5.2.4. By Drug Class
        • 10.3.5.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Pfizer, Inc.
    • 13.6.2. Novartis International AG
    • 13.6.3. Eli Lilly and Company
    • 13.6.4. Bristol Myers Squibb Company
    • 13.6.5. Teva Pharmaceutical Industries AG
    • 13.6.6. F. Hoffmann La Roche AG
    • 13.6.7. Mylan N.V.
    • 13.6.8. Celltrion Healthcare Co., Ltd
    • 13.6.9. Merck & Co., Inc.
    • 13.6.10. Teva Pharmaceutical Industries Ltd.

14. Strategic Recommendations